Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29675151 | 0.89 | GRIN2B (0.36) | PRMT5RPS6KB1 | |
| SCHEMBL13717800 | 0.80 | CSNK1E (0.45) | — | |
| SCHEMBL13718435 | 0.78 | MKNK1 (0.39) | TRPV3LRRK2PRMT5MKNK1 | |
| SCHEMBL13717565 | 0.77 | LRRK2 (0.40) | CSF1RTRPV3LRRK2MKNK1 | |
| SCHEMBL13717860 | 0.73 | LRRK2 (0.51) | LRRK2 | |
| SCHEMBL8742187 | 0.70 | KMT2A (0.48) | — | |
| SCHEMBL13717774 | 0.69 | PIK3CD (0.41) | RPS6KB1 | |
| SCHEMBL5093596 | 0.68 | MAPK14 (0.64) | MAPK14 | |
| SCHEMBL6055040 | 0.68 | MKNK1 (0.41) | MAPK14MKNK1 | |
| SCHEMBL29617744 | 0.67 | PIM1 (0.51) | CSF1RMAPK14MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352359-B2 | PI3K protein kinase inhibitors | RHIZEN PHARMACEUTICALS AG (CH) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352359-B2 | PI3K protein kinase inhibitors | PIK3CD, PIK3R5, PIK3CB | ALOX5AP 4319/4885FEN1 2411/4885CSF1R 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.